GSE197555 trametinib A-549 NCI-H460 1 v 2 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE197555_trametinib_A-549 NCI-H460_1_v_2_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE197555_trametinib_A-549 NCI-H460_1_v_2_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE197555_trametinib_A-549 NCI-H460_1_v_2_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE197555_trametinib_A-549 NCI-H460_1_v_2_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

CDGSH iron sulfur domain 3

Gene

CASTOR family member 3, pseudogene

Gene

FGD5 antisense RNA 1

Gene

HERC2 pseudogene 2

Gene

MIR34A host gene

Gene

FSHD region gene 1 family member C, pseudogene

Gene

activator of HSP90 ATPase homolog 2, pseudogene

Gene

HLA complex group 11

Gene

fer-1 like family member 4 (pseudogene)

Gene

solute carrier family 71 member 3, pseudogene

  • Gene

    CDGSH iron sulfur domain 3


  • Gene

    CASTOR family member 3, pseudogene


  • Gene

    FGD5 antisense RNA 1


  • Gene

    HERC2 pseudogene 2



  • Gene

    FSHD region gene 1 family member C, pseudogene


  • Gene

    activator of HSP90 ATPase homolog 2, pseudogene


  • Gene

    HLA complex group 11


  • Gene

    fer-1 like family member 4 (pseudogene)


  • Gene

    solute carrier family 71 member 3, pseudogene

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.